New Protocol: Pembrolizumab + chemotherapy for previously untreated advanced triple-negative breast cancer

New Protocol: Pembrolizumab + chemotherapy for previously untreated advanced triple-negative breast cancer

Placebo controlled phase 3 trial
Previously untreated locally recurrent inoperable or metastatic triple negative breast cancer
Pembrolizumab + chemo (n=566) vs. Placebo + chemo (n=281)
Chemo: Weekly PACLitaxel or weekly nab-PACLitaxel or CARBOplatin/gemcitabine
Median PFS:
7.5 vs. 5.6 mos in ITT population (NS)
9.7 vs. 5.6 mos in CPS >= 10 (HR:0.65 [0.49-0.86])
Grade 3-4 immune-mediated AEs: 5.5% vs. 0%

Journal of Clinical Oncology 2020;38(15_suppl):1000
Cortes J, et al. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
https://doi.org/10.1200/JCO.2020.38.15_suppl.1000

Reviewed by Ulas Darda Bayraktar, MD on Nov 18, 2020

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More